Dental Drugs
Dental Drugs is a clinical reference and anesthetic dosage calculator for dental professionals on iOS and Android.
The App DNA
What makes this app unique?
Users hire the app for rapid clinical decision support in high-stakes dental environments, where accuracy and offline access are critical to patient safety.
For Dental professionals and students in the USA and Canada.
What does it look like?
Key features
Calculates anesthetic volumes based on patient weight and cartridge size.
Step-by-step clinical guidelines for critical situations.
Database of 90+ dental drugs accessible without internet.
How much does it cost?
Subscription model gates all core clinical tools, which has triggered user backlash due to the removal of previously free content.
Velocity
Maintenance developmentinternationalizationperformanceShow more...
Dental Drugs currently operates at a maintenance cadence, with only two releases recorded over the last six months. The latest version focuses on subscription reliability and purchase restoration, while the previous release introduced internationalization support for Spanish speakers. Development appears focused on stability and platform-specific maintenance rather than frequent feature iteration. The current release frequency of approximately one update every three months suggests a stable but slow development cycle.
Who built it?
User Sentiment
What do users think recently?
Recent user voice shows a frustrated sentiment. Users appreciate long-term users value the comprehensive medical reference content for quick clinical decision support, but report transitioning from a free model to a mandatory yearly subscription frustrates long-term loyal users.
How are ratings & reviews evolving?
What users say, by theme
- Long-term users value the comprehensive medical reference content for quick clinical decision support
- Transitioning from a free model to a mandatory yearly subscription frustrates long-term loyal users
63 of 99 recent reviews analyzed · high confidence · Frustrated overall
Read the full review analysisUnlock 2 more frustration themes and 2 user requests, each backed by review evidence.
Access the full report for freeCompetition
Competitive landscape for Dental Drugs
How's the Education market?
Dental Drugs maintains a 4.66 rating on the iOS App Store. Its presence in international grossing charts, including #48 in the Philippines, indicates that its clinical tools have global demand despite the monetization friction.
Read the market outlookThe rivals identified
Unlock the deeper market read.
Access the full report for freeThe Analyst's Read
Key takeaways for Dental Drugs
Where is it heading?
The clinical reference market is consolidating around tools that offer reliable, offline access. Dental Drugs is currently exposed due to its aggressive monetization shift, which risks alienating the core user base before the next major update cycle.
- Technical failures in purchase restoration (reported by users) erode trust in the subscription model, which compounds the churn already visible post-update.
- The app's continued presence in international grossing charts indicates that the core clinical utility remains a high-value asset for dental professionals.
The SWOT
- Anesthetic dosage calculator provides a high-utility clinical barrier to entry
- Emergency management protocols offer standardized clinical guidance for dental practices
- Adding custom medication lists would increase clinical utility for power users
- Implementing a one-time purchase tier would capture users who refuse recurring subscriptions
Next best moves
Ship a one-time lifetime purchase option because users refuse recurring subscriptions for reference tools → increase conversion
+ 1 more prioritized moveThe counter-intuitive read
The app's high grossing rank in international markets…
Read the full takeSince the last report: The report reflects a shift from a purely negative outlook to a mixed one, acknowledging international market performance while maintaining concerns over subscription-related churn.
Bottom line
Dental Drugs retains a strong clinical moat through its specialized dosage and emergency tools, but the mandatory subscription model creates a churn risk that invites competitive disruption, so the PM should prioritize a one-time purchase tier to stabilize the user base.
Unlock 2 critical frictions, 2 market threats, 1 more prioritized move and the analyst’s take.
Access the full report for freeSources
- [1] App Store reviews
- [2] Developer website, source
Report last updated